Methodology breakdown computing — it will appear here on its own.
CytoMed Therapeutics Ltd (GDTC) is currently considered not halal (non-compliant), per our secondary compliance provider (last assessed 2026-06-01). See the full ratio breakdown and business-activity screen below for the reasoning. ⚠️ This provider verdict is about 3 months old (2026-06-01) — older than one reporting quarter, so it may predate the financial data shown below.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computing the full ratio and business-activity breakdown for GDTC — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 40.00 | NEUTRAL |
| Stochastic %K (14) | 17.91 | BUY |
| CCI (20) | -140.45 | BUY |
| Williams %R (14) | -82.09 | BUY |
| MACD (12,26,9) | -0.01 | SELL |
| ROC (10) | -18.76 | SELL |
| Momentum (10) | -0.19 | SELL |
| EMA (10) | 0.87 | SELL |
| SMA (10) | 0.88 | SELL |
| EMA (20) | 0.89 | SELL |
| SMA (20) | 0.91 | SELL |
| EMA (30) | 0.90 | SELL |
| SMA (30) | 0.89 | SELL |
| EMA (50) | 0.93 | SELL |
| SMA (50) | 0.92 | SELL |
| EMA (100) | 1.00 | SELL |
| SMA (100) | 0.99 | SELL |
| EMA (200) | 1.21 | SELL |
| SMA (200) | 1.10 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 41 |
| 🕐 1H | RANGING | 23 |
| ⏱ 15-Min | RANGING | 94 |
| ⏲ 5-Min | BULLISH | 234 |
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.